Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02448420
Title Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications

Her2-receptor positive breast cancer

Therapies

Eribulin + Trastuzumab

Fulvestrant + Palbociclib + Trastuzumab

Ado-trastuzumab emtansine + Trastuzumab

Palbociclib + Tamoxifen + Trastuzumab

Anastrozole + Palbociclib + Trastuzumab

Capecitabine + Trastuzumab

Gemcitabine + Trastuzumab

Palbociclib + Trastuzumab

Exemestane + Palbociclib + Trastuzumab

Trastuzumab + Vinorelbine

Letrozole + Palbociclib + Trastuzumab

Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.